ATM and neoplasm: Another phase I dose-escalation study (NCT03225105) assessed the safety and anti-tumor activity of the ATM inhibitor M3541 (50–300 mg) in combination with fractionated palliative radiotherapy (30 Gy in 10 fractions) in 15 patients with solid tumors (including two CRC patients) [114].